Rekha John, MD
Nephrology · Kinston, NCNPI 1619979846
Payments from drug & device makers
Across 1,112 payments — averaging $2102.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$860K
- Akebia Therapeutics Inc$652K
- Vertex$405K
- Bayer$167K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$127K
- Ardelyx, Inc.$78K
- plus $48K from 19 others
Across 7 payments — averaging $1092.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ardelyx, Inc.$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $859,963 |
| Akebia Therapeutics Inc | 886 | $651,838 |
| Vertex | 9 | $405,225 |
| Bayer | 80 | $167,392 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $127,410 |
| Ardelyx, Inc. | 39 | $78,389 |
| CSL Behring | 20 | $25,744 |
| Eli Lilly | 1 | $12,695 |
| Gilead | 1 | $8,500 |
| Otsuka America Pharmaceutical, Inc. | 4 | $161 |
| Vifor Pharma, Inc. | 7 | $116 |
| Novartis | 4 | $116 |
| Calliditas Therapeutics US Inc. | 4 | $103 |
| Amgen(2 entities) | 5 | $102 |
| Corvista Health, Inc. | 1 | $94 |
| Fresenius USA Marketing, Inc. | 4 | $70 |
| GSK | 2 | $66 |
| Shield Therapeutics Inc | 3 | $59 |
| Travere Therapeutics, Inc. | 4 | $42 |
| Boehringer Ingelheim | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Aurinia Pharma U.S., Inc. | 2 | $28 |
| Novo Nordisk | 1 | $26 |
| Sanofi | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $18 |
How this compares
$2,338,254 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Kinston
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Barry FreedmanWinston Salem$3.5M
- Manuel MonteroNew Bern$2.5M
- Nauman ShahidGreenville$2M
- Eric KirkWilmington$1.7M
- Amy MottlSanford$1.6M
- Amarnath KathresalDurham$1.6M
- Koithara Varkey ThomasJacksonville$1.5M
- Vimal DerebailChapel Hill$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.